Notes:

1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.02.2012.
2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
3 The entire net worth of the Company as on 31st March, 2011 has eroded. Therefore, as required under the provisions of the Sick Industrial Companies (Special Provisions) Act, 1985, the Company has made a reference to the Board for Industrial and Financial Reconstruction (BIFR) for determining measures that will be adopted with respect to the Company.
4 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
5 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
6 Previous year's figures have been re-grouped/re-classified, whereever necessary, so as to make them comparable with the current year's figures.
7 The Company identifies impairable assets at the year end for the purpose of arriving at impairment loss.

For MARKSANS PHARMA LIMITED

MARKSANS PHARMA LTD. MUMBAI-53

MARK SALDANHA
Managing Director.

Place: Mumbai.
Date: 13.02.2012
Visit us at www.marksanspharma.com